July 1, 2025

Higher Medicine announces the formation of Higher Therapeutics, a wholly-owned, Delaware-based subsidiary dedicated to developing novel treatments for Friedreich’s ataxia (FA)—a progressive, inherited neurodegenerative disorder driven by mitochondrial dysfunction. Higher Therapeutics will lead the development of our p38 MAP kinase inhibitor program, a small-molecule approach designed to modulate cellular stress responses and restore mitochondrial health in patients with FA.

The creation of Higher Therapeutics marks a significant milestone in our long-term strategy to address multiple rare and complex diseases through focused therapeutic programs and broad funding bases. This dedicated structure allows each team to operate with clear disease-area alignment and tailored development priorities while remaining united under a shared scientific vision.

Higher Medicine will continue to advance its epigenetic discovery and development efforts for Kabuki Syndrome, a rare pediatric disorder caused by disrupted gene regulation. Our lead program—an LSD1 inhibitor—targets chromatin remodeling mechanisms that contribute to developmental delay and neurological symptoms in Kabuki Syndrome.

Together, Higher Medicine and Higher Therapeutics embody our dual mission: to deliver disease-modifying therapies for pediatric and neurodegenerative conditions with high unmet need, and to unlock the potential of epigenetic and mitochondrial medicine for patients across the lifespan.

We remain committed to advancing these programs into the clinic and forging partnerships that accelerate progress toward healthier futures for the communities we serve.

Latest News

Our platform offers a variety of resources to keep you informed about our latest programs, key updates, achievements, and other significant developments in the field of healthcare and medicine.

Company Announcements
June 16, 2025

Higher Medicine Announces a Pre-Seed Builder Fund Investment from TEDCO

TEDCO's Pre-Seed Builder Fund, one of the state's marquee investment vehicles in Maryland, invested in Higher Medicine.

Company Announcements
June 12, 2025

Higher Medicine Announces Strategic Investment and Clinical Alliance with 5 Horizons Capital to Advance a Clinical Trial

Under the agreement, 5HC has committed to an equity investment valued at $181,492 in support of Higher Medicine’s upcoming Phase 1b/2a clinical trial in a rare pediatric disorder.

Company Announcements
June 2, 2025

Higher Medicine Joins BIO 2025 in Boston as a part of the Maryland Delegation

Higher Medicine attends the 2025 BIO International Convention from June 16–19 in Boston, MA, as part of the official Maryland delegation.

Company Announcements
June 2, 2025

Higher Medicine Announces Exclusive Option Agreement with Johns Hopkins Technology Ventures for Epigenetic Drug Candidate Screening Technology

Higher Medicine has entered into an exclusive option agreement with Johns Hopkins Technology Ventures (JHTV) to advance development of a proprietary histone reporter allele platform for epigenetic drug discovery.

Company Announcements
April 25, 2025

Higher Medicine Selected for the Maryland TEDCO SBIR/STTR Proposal Lab 2025 Cohort

Funded by TEDCO and administered by the leading experts in the field, Proposal Lab supports companies in securing competitive and prestigious NSF and other grants to advance their R&D portfolios.

Company Announcements
April 25, 2025

Higher Medicine Selected for HiveBio Accelerator Cohort

HiveBio Accelerator program offers world-class training, mentorship, and support to help scale Higher Medicine and secure follow-on funding.